Mega Genomics Limited disclosed a share repurchase on 2 October 2026, buying back 76,800 ordinary shares on the Hong Kong Stock Exchange at prices ranging from HKD 7.00 to HKD 7.09 per share. The transaction cost HKD 0.54 million on a volume-weighted average price of HKD 7.08.

Following the buyback, the company’s issued share capital (excluding treasury shares) fell 0.03% to 222.05 million shares, while treasury shares rose to 2.25 million. Total issued shares remain unchanged at 224.30 million.

The repurchase forms part of the mandate approved on 21 May 2026, which authorises the company to repurchase up to 22.43 million shares. To date, 2.25 million shares—equivalent to 1.00% of the issued share base at mandate date—have been repurchased under this authority.

All repurchased shares are being held in treasury; none were cancelled as of the reporting date. Under listing rules, Mega Genomics is restricted from issuing new shares or disposing of treasury shares until 1 November 2026.